Induction of Myasthenia Gravis, Myositis, and Insulin-Dependent Diabetes Mellitus by High-Dose Interleukin-2 in a Patient With Renal Cell Cancer

Journal of Immunotherapy

Volumn 25, Issue 4, 2002, Pages 373-378

  Fraenkel, Paula G ^a   Rutkove, Seward B ^a   Matheson, Jean K ^a   Fowkes, Mary ^a   Cannon, Marie E ^b   Patti, Mary Elizabeth ^b   Atkins, Michael B ^b   Gollob, Jared A ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Autoimmunity; Interleukin 2; Myasthenia gravis; Renal cell cancer

Indexed keywords

CELL ANTIGEN; CHOLINERGIC RECEPTOR; CORTICOSTEROID; INSULIN; MUSCLE ANTIBODY; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 12; INTERLEUKIN 2;

ACETYLCHOLINE RELEASE; ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CASE REPORT; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHYROIDISM; IMMUNOLOGICAL TOLERANCE; INSULIN METABOLISM; KIDNEY CARCINOMA; MALE; MELANOMA; MYASTHENIA GRAVIS; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL; PLASMAPHERESIS; POLYMYOSITIS; PRIORITY JOURNAL; SKELETAL MUSCLE; STEROID THERAPY; VITILIGO; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TUMOR; LUNG TUMOR; METASTASIS; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

CARCINOMA, RENAL CELL; CASE REPORT; DIABETES MELLITUS, INSULIN-DEPENDENT; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN; INTERLEUKIN-2; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGE; MYASTHENIA GRAVIS; MYOSITIS; DIABETES MELLITUS, TYPE 1; HUMANS; MIDDLE AGED;

EID: 0035990421     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200207000-00009     Document Type: Article

References (25)

1. Henney CS, Kuribayashi K, Kern DE, et al. Interleukin-2 augments natural killer cell activity. Nature 1981; 291:335-8.
2. Grimm EA, Mazumder A, Zhang HZ, et al. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155:1823-41.
3. Rosenberg SA, Mule JJ. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2. Surgery 1985; 98:437-44.
4. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316:889-97.
5. West WH, Tauer KW, Yannelli JR, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316:898-905.
6. Weijl NI, Van der Harst D, Brand A, et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol 1993; 11:1376-83.
7. Atkins M, Mier JW, Parkinson DR, et al. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 1988; 318:1557-63.
8. Mattijssen VJ, De Mulder PH, Van Liessum PA, et al. Hypothyroidism and goiter in a patient during treatment with interleukin-2. Cancer 1990; 65:2686-8.
9. Vardi P, Dib SA, Tuttleman M, et al. Competitive insulin autoantibody assay. Prospective evaluation of subjects at high risk for development of type I diabetes mellitus. Diabetes 1987; 36:1286-91.
10. Payton MA, Hawkes CJ, Christie MR. Relationship of the 37,000-and 40,000-M(r) tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). J Clin Invest 1995; 96:1506-11.
11. Grubin CE, Daniels T, Toivola B, et al. A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 1994; 37:344-50.
12. Kohanski RA, Andrews JP, Wins P, et al. A simple quantitative assay of 125I-labeled alpha-bungarotoxin binding to soluble and membrane-bound acetylcholine receptor protein. Anal Biochem 1977; 80:531-9.
13. Drachman DB, Adams RN, Josifek LF, et al. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med 1982; 307:769-75.
14. Lyons BW, Wu LL, Astill ME, et al. Development of an assay for modulating anti-acetylcholine receptor autoantibodies using human rhabdomyosarcoma cell line. J Clin Lab Anal 1998; 12:315-9.
15. Ferrone, S.a.S., B.G. HLA typing: methodology and clinical aspects. Vol. I and II. Boca Raton: CRC Press Inc., 1982.
16. Shtauvere A, Rumba I, Dzivite I, et al. HLA-DR and -DQ gene polymorphism in Latvian patients with insulin-dependent diabetes mellitus. Tissue Antigens 1998; 52:385-8.
17. Bergstrom RW, Atkins MB, Mier JW, et al. Augmentation of insulin autoantibodies following interleukin-2 and lymphokine activated killer cell therapy. J Clin Lab Immunol 1990; 31:189-93.
18. Soni N, Meropol NJ, Porter M, et al. Diabetes mellitus induced by low-dose interleukin-2. Cancer Immunol Immunother 1996; 43:59-62.
19. Allison J, McClive P, Oxbrow L, et al. Genetic requirements for acceleration of diabetes in non-obese diabetic mice expressing interleukin-2 in islet beta-cells. Eur J Immunol 1994; 24:2535-41.
20. Esteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer 1995; 76:1219-23.
21. Wurzer H, Brandstatter G, Harnoncourt K, et al. Paraneoplastic polymyositis associated with a renal carcinoma. J Intern Med 1993; 234:521-4.
22. Gemlo BT, Palladino MA, Jaffe HS, et al. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res 1988; 48:5864-7.
23. Beniers AJ, Peelen WP, Debruyne FM, et al. HLA-class-I and -class-II expression on renal tumor xenografts and the relation to sensitivity for alpha-IFN, gamma-IFN and TNF. Int J Cancer 1991; 48:709-16.
24. Kida K, Hayashi M, Yamada I, et al. Heterogeneity in myasthenia gravis: HLA phenotypes and autoantibody responses in ocular and generalized types. Ann Neurol 1987; 21:274-8.
25. Phan GQ, Attia P, Steinberg SM, et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001; 19:3477-82.